Research location
Magdeburg
Germany
Advertisement
Research activity in Magdeburg
GermanyCureCurrent currently publishes aggregate city-level research activity for this location: 299 trials and 354 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Magdeburg
299 linked trials · page 1 of 6A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEFNCT07761117 · 2026-08-24 · 1 site observation
RECRUITING
A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or OverweightNCT07784270 · 2026-08-20 · 1 site observation
RECRUITING
A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes MellitusNCT07784725 · 2026-08-19 · 1 site observation
RECRUITING
A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus on Background InsulinNCT07664553 · 2026-07-08 · 1 site observation
RECRUITING
AMAZE 1: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Lose WeightNCT07339423 · 2026-02-24 · 1 site observation
RECRUITING
An Open-label Study of AZD0120 in Adults With Multiple SclerosisNCT07224373 · 2025-12-09 · 1 site observation
RECRUITING
Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular DiseaseNCT07181109 · 2025-09-22 · 1 site observation
RECRUITING
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or ObesityNCT07037433 · 2025-07-25 · 1 site observation
RECRUITING
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular DiseaseNCT07064473 · 2025-07-22 · 1 site observation
RECRUITING
A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis.NCT06916806 · 2025-05-01 · 1 site observation
RECRUITING
Cyclosporine In Takotsubo SyndromeNCT05946772 · 2025-02-01 · 1 site observation
RECRUITING
UmbREALung - A Retrospective and Prospective, Observational, Real World Multi-cohort Study of Patients With Non-small Cell Lung Cancer (NSCLC) Initiating Approved Drugs Developed by AZ or as Part of an AZ AllianceNCT06726720 · 2024-12-16 · 1 site observation
RECRUITING
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLCNCT06627647 · 2024-11-27 · 1 site observation
RECRUITING
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)NCT06692738 · 2024-11-18 · 1 site observation
RECRUITING
A Study to Investigate Effects of Ocrelizumab Treatment on Neurofilament Light Chain (NfL) Levels and Participant Satisfaction in Participants With Multiple Sclerosis (MS)NCT06780150 · 2024-09-26 · 2 site observations
RECRUITING
Real-world Experience With Lutetium Vipivotide Tetraxetan in Metastatic Castration Resistant Prostate CancerNCT06517719 · 2024-09-04 · 1 site observation
RECRUITING
PROVIDENCE - Prospective Non-interventional Study (NIS) to Examine Patient-reported Outcomes and Real-world Clinical Data in Patients With HER2-positive, HER2-low or HER2-ultralow Unresectable or Metastatic Breast Cancer Treated With Trastuzumab DeruxtecanNCT05573893 · 2023-09-12 · 1 site observation
RECRUITING
Alleviant ALLAY-HF StudyNCT05685303 · 2023-01-10 · 1 site observation
RECRUITING
A NIS Evaluating Various Injectable and Oral Treatments in Patients With Relapsing Multiple SclerosisNCT05344469 · 2022-05-10 · 1 site observation
RECRUITING
AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Excess Body Weight and Type 2 Diabetes Lose WeightNCT07400107 · 2026-05-20 · 1 site observation
NOT_YET_RECRUITING
A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's DiseaseNCT07170150 · 2025-11-12 · 1 site observation
ACTIVE_NOT_RECRUITING
A Dose Finding Study With an Anti-TSLP Antibody (GSK5784283) in Adults Aged 18 to 75 Years of Age With Uncontrolled AsthmaNCT06748053 · 2025-02-10 · 1 site observation
ACTIVE_NOT_RECRUITING
A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With AsthmaNCT06664619 · 2024-12-12 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2)NCT06516965 · 2024-10-10 · 1 site observation
ACTIVE_NOT_RECRUITING
Real World Use of Tocilizumab Biosimilar studYNCT06247722 · 2024-03-05 · 1 site observation
ACTIVE_NOT_RECRUITING
Study to Assess Safety and Efficacy of PRI-002 in Patients With MCI to Mild Dementia Due to Alzheimer's Disease (AD)NCT06182085 · 2024-02-15 · 1 site observation
COMPLETED
Real-World Clinical Experience of Patients With Metastatic Castration-Resistant Prostate Cancer Treated With Olaparib + Abiraterone (PROceed)NCT06380738 · 2024-02-14 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study to Assess Safety & Effectiveness of Tovinontrine in Chronic Heart Failure With Reduced Ejection Fraction (Cycle-1-REF)NCT06215911 · 2024-02-13 · 1 site observation
COMPLETED
Safety & Effectiveness of Tovinontrine in Chronic Heart Failure With Preserved Ejection Fraction (Cycle-2-PEF)NCT06215586 · 2024-02-13 · 1 site observation
COMPLETED
Comparison Between CHF5993 pMDI 200/6/12.5 µg HFA-152a VS CHF5993 pMDI 200/6/12.5 µg HFA-134a in Subjects With Asthma (TRECOS).NCT06264674 · 2023-11-27 · 1 site observation
COMPLETED
A Trial to Learn How Safe AZD9550 Monotherapy and Combined With AZD6234 is in People With or Without Type 2 Diabetes Who Are Living With Obesity and OverweightNCT06151964 · 2023-09-29 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD)NCT05878769 · 2023-06-28 · 1 site observation
ACTIVE_NOT_RECRUITING
A Trial Comparing Docetaxel 75 mg/m2 (3w) Versus Docetaxel 50 mg/m2 (2w) in Combination With Darolutamide + ADT in mHSPC PatientsNCT05676203 · 2023-05-16 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular RiskNCT05803421 · 2023-04-03 · 1 site observation
COMPLETED
Characterizing Guideline Adoption and Treatment Quality in Clinical Routine of German HFrEF CareNCT06004453 · 2023-04-03 · 1 site observation
COMPLETED
A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma (EXHALE-3)NCT05813288 · 2023-03-27 · 1 site observation
TERMINATED
Safety and Tolerability of a Timolol Releasing Intraocular Implant in Subjects With Primary Open-angle GlaucomaNCT06321562 · 2023-03-01 · 1 site observation
TERMINATED
Electrical Stimulation for the Treatment of GlaucomaNCT05626491 · 2023-02-28 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study to Evaluate Astegolimab in Participants With Chronic Obstructive Pulmonary DiseaseNCT05595642 · 2022-12-29 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study to Assess the Safety of Budesonide/Glycopyrronium/Formoterol Fumarate With a Next-Generation Propellant in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary DiseaseNCT05573464 · 2022-09-27 · 1 site observation
COMPLETED
A Study Comparing Abelacimab to Apixaban in the Treatment of Cancer-associated VTENCT05171049 · 2022-05-05 · 1 site observation
TERMINATED
An Open-Label Extension Study of GSK3511294 (Depemokimab) in Participants Who Were Previously Enrolled in 206713 (NCT04719832) or 213744 (NCT04718103)NCT05243680 · 2022-03-01 · 1 site observation
COMPLETED
A 24-Week Efficacy and Safety Study to Assess Budesonide and Formoterol Fumarate Metered Dose Inhaler in Adult and Adolescent Participants With Inadequately Controlled Asthma (VATHOS)NCT05202262 · 2022-01-12 · 1 site observation
COMPLETED
A Study to Investigate the Safety, Tolerability and Effects of AZD8630 in Healthy Subjects and Subjects With Asthma on Inhaled Corticosteroids and Long-acting Beta-agonistsNCT05110976 · 2021-12-16 · 1 site observation
COMPLETED
Prospective Observational Study of Filgotinib in Subjects With Rheumatoid ArthritisNCT04871919 · 2021-05-11 · 1 site observation
ACTIVE_NOT_RECRUITING
Placebo-controlled Efficacy and Safety Study of GSK3511294 (Depemokimab) in Participants With Severe Asthma With an Eosinophilic PhenotypeNCT04719832 · 2021-03-17 · 1 site observation
COMPLETED
A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic PhenotypeNCT04718389 · 2021-01-26 · 1 site observation
COMPLETED
Omission of SLNB in Triple-negative and HER2-positive Breast Cancer Patients With rCR and pCR in the Breast After NASTNCT04101851 · 2021-01-13 · 1 site observation
ACTIVE_NOT_RECRUITING
Adjuvant Apalutamide in Subjects With High-risk Localized or Locally Advanced Prostate Cancer After Radical ProstatectomyNCT04295447 · 2020-12-10 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)NCT04622319 · 2020-12-04 · 1 site observation
ACTIVE_NOT_RECRUITING
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.